EFFICACY AND SAFETY OF 12 WEEKS OF SOFOSBUVIR/VELPATASVIR WITH OR WITHOUT RIBAVIRIN IN GENOTYPE 3 HEPATITIS C VIRUS-INFECTED PATIENTS: A REAL-WORLD STUDY OF CHINA AND SAFETY OF 12 WEEKS OF SOFOSBUVIR/VELPATASVIR WITH OR WITHOUT RIBAVIRIN IN GENOTYPE 3 HEPATITIS C VIRUS-INFECTED PATIENTS: A REAL-WORLD STUDY OF CHINA
第一作者机构：[1]First Peoples Hosp Yunnan Prov, Dept Infect Dis & Liver Dis, Kunming, Yunnan, Peoples R China[2]First Peoples Hosp Yunnan Prov, Kunming, Yunnan, Peoples R China
推荐引用方式(GB/T 7714)：
Yue Wei,Liu Li,Xiao An,et al.EFFICACY AND SAFETY OF 12 WEEKS OF SOFOSBUVIR/VELPATASVIR WITH OR WITHOUT RIBAVIRIN IN GENOTYPE 3 HEPATITIS C VIRUS-INFECTED PATIENTS: A REAL-WORLD STUDY OF CHINA AND SAFETY OF 12 WEEKS OF SOFOSBUVIR/VELPATASVIR WITH OR WITHOUT RIBAVIRIN IN GENOTYPE 3 HEPATITIS C VIRUS-INFECTED PATIENTS: A REAL-WORLD STUDY OF CHINA[J].HEPATOLOGY.2021,74:589A-589A.
APA：
Yue, Wei,Liu, Li,Xiao, An,Du, Yingrong,Gao, Jianpeng...&Geng, Jiawei.(2021).EFFICACY AND SAFETY OF 12 WEEKS OF SOFOSBUVIR/VELPATASVIR WITH OR WITHOUT RIBAVIRIN IN GENOTYPE 3 HEPATITIS C VIRUS-INFECTED PATIENTS: A REAL-WORLD STUDY OF CHINA AND SAFETY OF 12 WEEKS OF SOFOSBUVIR/VELPATASVIR WITH OR WITHOUT RIBAVIRIN IN GENOTYPE 3 HEPATITIS C VIRUS-INFECTED PATIENTS: A REAL-WORLD STUDY OF CHINA.HEPATOLOGY,74,
MLA：
Yue, Wei,et al."EFFICACY AND SAFETY OF 12 WEEKS OF SOFOSBUVIR/VELPATASVIR WITH OR WITHOUT RIBAVIRIN IN GENOTYPE 3 HEPATITIS C VIRUS-INFECTED PATIENTS: A REAL-WORLD STUDY OF CHINA AND SAFETY OF 12 WEEKS OF SOFOSBUVIR/VELPATASVIR WITH OR WITHOUT RIBAVIRIN IN GENOTYPE 3 HEPATITIS C VIRUS-INFECTED PATIENTS: A REAL-WORLD STUDY OF CHINA".HEPATOLOGY 74.(2021):589A-589A
医学